Literature DB >> 9465841

The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent.

B Kaplan1, H U Meier-Kriesche, K L Napoli, B D Kahan.   

Abstract

INTRODUCTION: Sirolimus and cyclosporine (INN, ciclosporin) share the same cytochrome P4503A metabolic pathways, and both drugs are substrates for p-glycoprotein countertransport. These factors most likely affect the bioavailability of both drugs. This study served to examine whether the timing of the administration of cyclosporine and sirolimus might significantly affect the relative bioavailability of one or both of these drugs.
METHODS: In this randomized crossover trial, 24 stable kidney transplant recipients who were treated after transplant with a combination of sirolimus, cyclosporine, and prednisone for at least 3 months before study initiation, received individualized doses of sirolimus once daily and cyclosporine in the microemulsion formulation twice a day. A total of 20 patients completed the full crossover design. Patients were randomized to one of two dosing schedules: 10 of the patients who completed the study received the morning doses of sirolimus and cyclosporine concomitantly for the first 7 days (schedule I), and from days 8 to 14 the sirolimus dose was administered 4 hours after the morning cyclosporine dose. Ten of the patients received the sirolimus dose 4 hours after the morning cyclosporine dose for the first 7 days (schedule II), and from days 8 to 14 they received concomitant morning doses of cyclosporine and sirolimus. Pharmacokinetic profiles of sirolimus and cyclosporine performed on all patients on days 7, 14, and 15 yielded the area under the concentration-time curve (AUC), peak concentration (Cmax), time to Cmax (tmax), trough cyclosporine concentration (Co), and trough sirolimus concentration (Co) values.
RESULTS: Sirolimus AUC and sirolimus trough levels were consistently and significantly higher when both cyclosporine and sirolimus were administered concomitantly than when they were administered 4 hours apart. No effect attributable to timing of drug administration could be found on cyclosporine pharmacokinetic parameters.
CONCLUSION: This study shows that the relative timing of administration of cyclosporine and sirolimus significantly affects the blood concentrations of sirolimus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9465841     DOI: 10.1016/S0009-9236(98)90120-5

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome.

Authors:  Philipp A Lang; Ortraud Beringer; Jan P Nicolay; Oliver Amon; Daniela S Kempe; Tobias Hermle; Philipp Attanasio; Ahmad Akel; Richard Schäfer; Björn Friedrich; Teut Risler; Matthias Baur; Christoph J Olbricht; Lothar Bernd Zimmerhackl; Peter F Zipfel; Thomas Wieder; Florian Lang
Journal:  J Mol Med (Berl)       Date:  2006-04-19       Impact factor: 4.599

2.  Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients.

Authors:  Zheng Jiao; Xiao-jin Shi; Zhong-dong Li; Ming-kang Zhong
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

3.  Induction of eryptosis by cyclosporine.

Authors:  Olivier M Niemoeller; Ahmad Akel; Philipp A Lang; Philipp Attanasio; Daniela S Kempe; Tobias Hermle; Malgorzata Sobiesiak; Thomas Wieder; Florian Lang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-09-22       Impact factor: 3.000

Review 4.  Clinical pharmacokinetics of sirolimus.

Authors:  K Mahalati; B D Kahan
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Sirolimus: the evidence for clinical pharmacokinetic monitoring.

Authors:  Sunita Bond Stenton; Nilufar Partovi; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

6.  Mechanistic Target of Rapamycin (mTOR) Inhibitors.

Authors:  Denise Wang; Howard J Eisen
Journal:  Handb Exp Pharmacol       Date:  2022

Review 7.  Nanomedicines in renal transplant rejection--focus on sirolimus.

Authors:  Li-Jiuan Shen; Fe-Lin Lin Wu
Journal:  Int J Nanomedicine       Date:  2007

Review 8.  Pediatric liver transplantation.

Authors:  Marco Spada; Silvia Riva; Giuseppe Maggiore; Davide Cintorino; Bruno Gridelli
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

9.  Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients.

Authors:  Mark D Pescovitz; Flavio Vincenti; Marquis Hart; Larry Melton; John Whelchel; Shamkant Mulgaonkar; Diane McKay; Mimi Leung; Elizabeth Calleja; M René Bouw
Journal:  Br J Clin Pharmacol       Date:  2007-06-06       Impact factor: 4.335

Review 10.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.